keyword
MENU ▼
Read by QxMD icon Read
search

adherence treatment schizophrenia

keyword
https://www.readbyqxmd.com/read/28543089/treatments-for-people-living-with-schizophrenia-in-sub-saharan-africa-an-adapted-realist-review
#1
REVIEW
S Chidarikire, M Cross, I Skinner, M Cleary
AIM: To identify the treatments and interventions available and their impact on people living with schizophrenia in Sub-Saharan Africa. BACKGROUND: Help-seeking behaviour and the choice of treatment are largely influenced by socio-cultural factors and beliefs about the causes of mental illness. This review addresses the gap in knowledge regarding the treatment options available to people living with schizophrenia in Sub-Saharan Africa. DESIGN: Adapted realist literature review...
May 25, 2017: International Nursing Review
https://www.readbyqxmd.com/read/28533580/olanzapine-induced-neuroleptic-malignant-syndrome
#2
Seyedhamze Hosseini, Forouzan Elyasi
Neuroleptic malignant syndrome (NMS) is a rare but life-threatening idiosyncratic side effect resulting from neuroleptic drugs. NMS mainly occurs in patients treated with high-potency typical antipsychotics, but rarely caused by atypical antipsychotics. Although NMS is less common with atypical antipsychotic, but it seems that its incidence is rising due to increased administration of such drugs. We present the case of a 27-year-old man with a history of paranoid schizophrenia that showed signs consistent with NMS that occurred after treatment with olanzapine...
May 2017: Iranian Journal of Medical Sciences
https://www.readbyqxmd.com/read/28529220/clinical-correlates-of-treatment-response-among-patients-with-schizophrenia-in-a-tertiary-nigerian-hospital
#3
Mark Sunday Ezeme, Richard Uwakwe, Appolos Chidi Ndukuba, Monday N Igwe, Paul Chigozie Odinka, Kennedy Amadi, Nichodemus O Obayi
A significant proportion of patients treated for schizophrenia respond poorly to medication. Few studies have systematically examined the impact of clinical characteristics of patients to antipsychotic response in our environment. The study aimed to identify clinical variables associated with response in patients with schizophrenia. A total of 172 participants diagnosed with schizophrenia, placed on antipsychotics, who presented for the first time to the hospital or have stopped medication in the preceding six months, whose responses were assessed after four to six weeks were studied...
2017: Journal of Health Care for the Poor and Underserved
https://www.readbyqxmd.com/read/28523839/algorithm-based-pharmacotherapy-for-first-episode-schizophrenia-involuntarily-hospitalized-a-retrospective-analysis-of-real-world-practice
#4
Bunta Yoshimura, Kojiro Sato, Manabu Takaki, Norihito Yamada
BACKGROUND: Little is known about the clinical outcomes of severely ill patients with first-episode schizophrenia spectrum disorders (FES) who are considered to lack the capacity to consent to clinical trials. We investigated the feasibility of an algorithm-based pharmacotherapy (ABP) and clinical outcomes of patients with FES involuntarily hospitalized and treated with ABP. METHODS: We conducted a retrospective chart review of 160 patients admitted involuntarily between October 2012 and October 2015...
May 19, 2017: Early Intervention in Psychiatry
https://www.readbyqxmd.com/read/28470156/-effects-of-a-relapse-prevention-program-on-insight-empowerment-and-treatment-adherence-in-patients-with-schizophrenia
#5
Jaewon Joung, Sungjae Kim
PURPOSE: The purpose of this study was to develop a relapse prevention program (RPP) and examine the effects of the RPP on insight, empowerment, and treatment adherence in patients with schizophrenia. METHODS: A non-equivalent control group pretest-posttest design was used. Participants were 54 inpatients who had a diagnosis of schizophrenia (experimental group: 26, control group: 28). The study was carried out from February 7, 2012 to February 6, 2013. Over a 10-day period prior to discharge each participant in the experimental group received three one-hour sessions of RPP a one-to-one patient-nurse interaction...
April 2017: Journal of Korean Academy of Nursing
https://www.readbyqxmd.com/read/28464848/experiences-perspectives-and-priorities-of-people-with-schizophrenia-spectrum-disorders-regarding-sleep-disturbance-and-its-treatment-a-qualitative-study
#6
Sophie Faulkner, Penny Bee
BACKGROUND: Sleep problems are very common in people with schizophrenia spectrum disorders, and impact negatively on functioning and wellbeing. Research regarding interventions to improve sleep in this population has been lacking. Little is known regarding these patient's perspectives on sleep problems and their treatment, providing very little foundation on which to develop acceptable and patient-centred treatments. METHODS: This study aims to explore perspectives and priorities of participants with schizophrenia spectrum disorders regarding sleep and sleep disturbance, and their perspectives on existing treatments...
May 2, 2017: BMC Psychiatry
https://www.readbyqxmd.com/read/28463346/an-algorithmic-approach-to-the-management-of-insomnia-in-patients-with-schizophrenia
#7
Ridha Joober, Katherine Cole, Karim Tabbane, Diane B Boivin
BACKGROUND: Insomnia is an important problem in patients with schizophrenia and is an emerging area of interest for researchers. We propose a treatment algorithm that synthesizes the various psychological and pharmacological interventions for insomnia in this population. METHODS: Our selective literature review incorporates English language articles from 4 medicine databases through May 2016. Selected articles discuss risk factors and treatments for insomnia, as well as comorbid sleep disorders that coexist in this population...
May 2017: Annals of Clinical Psychiatry: Official Journal of the American Academy of Clinical Psychiatrists
https://www.readbyqxmd.com/read/28449560/assessment-of-the-latent-adverse-events-of-antipsychotic-treatment-using-a-subjective-questionnaire-in-japanese-patients-with-schizophrenia
#8
Masakazu Hatano, Hiroyuki Kamei, Azusa Kato, Ippei Takeuchi, Manako Hanya, Junji Uno, Shigeki Yamada, Kiyoshi Fujita, Nakao Iwata
Objective: The adverse effects of antipsychotic agents can have a marked influence on medication adherence. In this study, we. investigated the adverse events of antipsychotics that are less likely to be reported by patients and the reasons why such symptoms remain latent. Methods: Data were collected by interviewing patients using a subjective questionnaire, and the associations between unreported symptoms and background factors were investigated. Results: A total of 306 patients with schizophrenia or schizoaffective disorder were examined...
May 31, 2017: Clinical Psychopharmacology and Neuroscience: the Official Scientific Journal of the Korean College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/28395674/antipsychotic-treatment-resistance-in-first-episode-psychosis-prevalence-subtypes-and-predictors
#9
A Demjaha, J M Lappin, D Stahl, M X Patel, J H MacCabe, O D Howes, M Heslin, U A Reininghaus, K Donoghue, B Lomas, M Charalambides, A Onyejiaka, P Fearon, P Jones, G Doody, C Morgan, P Dazzan, R M Murray
BACKGROUND: We examined longitudinally the course and predictors of treatment resistance in a large cohort of first-episode psychosis (FEP) patients from initiation of antipsychotic treatment. We hypothesized that antipsychotic treatment resistance is: (a) present at illness onset; and (b) differentially associated with clinical and demographic factors. METHOD: The study sample comprised 323 FEP patients who were studied at first contact and at 10-year follow-up...
April 11, 2017: Psychological Medicine
https://www.readbyqxmd.com/read/28382557/long-acting-injectable-antipsychotics-in-schizophrenia-literature-review-and-practical-perspective-with-a-focus-on-aripiprazole-once-monthly
#10
REVIEW
Enrico Biagi, Enrico Capuzzi, Fabrizia Colmegna, Alessandra Mascarini, Giulia Brambilla, Alessandra Ornaghi, Jacopo Santambrogio, Massimo Clerici
INTRODUCTION: Prevention of relapse is a major challenge in schizophrenia, a disease characterized by poor adherence to antipsychotic medication leading to multiple rehospitalizations and a substantial burden-of-care. METHODS: We narratively review published clinical data from the development of long-acting injectable (LAI) formulations of antipsychotic drugs and examine the comparative effectiveness of oral versus LAIs in schizophrenia, with a focus on the second-generation LAI antipsychotic aripiprazole...
April 5, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28374699/-comparative-evaluation-of-clinical-and-economic-efficiency-of-paliperidone-in-various-dosage-forms-used-in-patients-with-schizophrenia
#11
I N D'yakov, S K Zyryanov
AIM: To evaluate clinical and economic efficacy of schizophrenia treatment with three forms of paliperidone (peroral form, intramuscular injections once a month and once in three month). MATERIAL AND METHODS: Pharmacoeconomic analysis based on the results of earlier foreign randomized clinical studies on paliperidone in treatment of schizophrenia was carried out. Indirect comparison of different medication forms of paliperidone compared to placebo was performed...
2017: Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova
https://www.readbyqxmd.com/read/28356723/treatment-patterns-in-medicaid-patients-with-schizophrenia-initiated-on-a-first-or-second-generation-long-acting-injectable-versus-oral-antipsychotic
#12
Dominic Pilon, Kruti Joshi, Neeta Tandon, Marie-Hélène Lafeuille, Rhiannon L Kamstra, Bruno Emond, Patrick Lefebvre
BACKGROUND: Poor antipsychotic (AP) adherence is a key issue in patients with schizophrenia. First-generation antipsychotic (FGA) and second-generation antipsychotic (SGA) long-acting injectable therapies (LAI) may improve adherence compared to oral antipsychotics (OAP). The objective of the study was to compare treatment adherence and persistence in Medicaid patients with schizophrenia initiated on first-generation long-acting injectable therapies (FGA-LAI) or second-generation long-acting injectable therapies (SGA-LAI) versus OAP...
2017: Patient Preference and Adherence
https://www.readbyqxmd.com/read/28344764/atypical-antipsychotics-recent-research-findings-and-applications-to-clinical-practice-proceedings-of-a-symposium-presented-at-the-29th-annual-european-college-of-neuropsychopharmacology-congress-19-september-2016-vienna-austria
#13
REVIEW
Robin Murray, Christoph U Correll, Gavin P Reynolds, David Taylor
Available evidence suggests that second-generation atypical antipsychotics are broadly similar to first-generation agents in terms of their efficacy, but may have a more favourable tolerability profile, primarily by being less likely to cause extrapyramidal symptoms. However, atypical antipsychotics are variably associated with disturbances in the cardiometabolic arena, including increased body weight and the development of metabolic syndrome, which may reflect differences in their receptor binding profiles...
March 2017: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/28342943/would-i-take-antipsychotics-if-i-had-psychotic-symptoms-examining-determinants-of-the-decision-to-take-antipsychotics
#14
Fabrice Berna, Anja S Göritz, Pierre-Michel Llorca, Pierre Vidailhet, Guillaume Fond, Steffen Moritz
Poor adherence to treatment in schizophrenia is mainly associated to patients-related factors. However, social negative representations of schizophrenia and its treatment may also contribute to patients' decision to take or not to take antipsychotics. A web-based study on 1,807 participants was conducted during which participants imagined that they had a particular chronic illness based on clinical vignettes (mental illnesses: schizophrenia, depression; somatic illnesses: multiple sclerosis, rheumatoid arthritis)...
March 22, 2017: Progress in Neuro-psychopharmacology & Biological Psychiatry
https://www.readbyqxmd.com/read/28325572/lipid-profile-disturbances-in-antipsychotic-naive-patients-with-first-episode-non-affective-psychosis-a-systematic-review-and-meta-analysis
#15
REVIEW
Błażej Misiak, Bartłomiej Stańczykiewicz, Łukasz Łaczmański, Dorota Frydecka
BACKGROUND: Dyslipidaemia is one of the most prevalent metabolic disturbances observed in schizophrenia patients and has been largely attributed to the effects of poor lifestyle habits and adverse effects of antipsychotic treatment. However, less is known whether patients with first-episode non-affective psychosis (FENP) present subthreshold indices of dyslipidaemia. Therefore, we tested the hypothesis whether subclinical lipid profile alterations occur already in antipsychotic-naïve FENP patients...
March 18, 2017: Schizophrenia Research
https://www.readbyqxmd.com/read/28287773/alcohol-use-and-service-utilization-among-veterans-in-treatment-for-schizophrenia
#16
Eric R Pedersen, Wenjing Huang, Amy N Cohen, Alexander S Young
Comorbid alcohol and drug use disorders are treatable and have substantial effects on outcomes and health care utilization in people with schizophrenia. While these substance use disorders (SUDs) are thought to be common in patients with schizophrenia, it has been difficult to characterize prevalence and treatment utilization of this population, since administrative data and medical records may not identify patients with schizophrenia who have an SUD diagnosis. In this study, we used an in-person, population-based survey of 801 individuals with schizophrenia who were in treatment within the Veterans Health Administration (VHA) to inform service delivery for patients with these problems...
March 13, 2017: Psychological Services
https://www.readbyqxmd.com/read/28267822/occlusal-dysesthesia-a-clinical-report-on-the-psychosomatic-management-of-a-japanese-patient-cohort
#17
Hitoshi Oguchi, Yu Yamauchi, Yasuyo Karube, Nobue Suzuki, Katsushi Tamaki
PURPOSE: A cohort of Japanese patients diagnosed with occlusal dysesthesia (OD) was clinically analyzed for psychosomatic background, management, and treatment outcome. MATERIALS AND METHODS: The study group comprised 61 patients (17 men and 44 women) who met the OD criteria. Treatment outcomes were categorized as improvement, interruption, and transfer to another department. RESULTS: The diagnosed OD was resolved in 25 patients (41%), 20 patients (33%) discontinued treatment, 13 (21%) were referred or transferred to other specialties such as psychiatry, and 3 (5%) continued to receive treatment following an engagement period of 3 months, 2 years, and 5 years, respectively...
March 2017: International Journal of Prosthodontics
https://www.readbyqxmd.com/read/28258047/mobile-phone-apps-for-smoking-cessation-quality-and-usability-among-smokers-with-psychosis
#18
Joelle C Ferron, Mary F Brunette, Pamela Geiger, Lisa A Marsch, Anna M Adachi-Mejia, Stephen J Bartels
BACKGROUND: Smoking is one of the top preventable causes of mortality in people with psychotic disorders such as schizophrenia. Cessation treatment improves abstinence outcomes, but access is a barrier. Mobile phone apps are one way to increase access to cessation treatment; however, whether they are usable by people with psychotic disorders, who often have special learning needs, is not known. OBJECTIVE: Researchers reviewed 100 randomly selected apps for smoking cessation to rate them based on US guidelines for nicotine addiction treatment and to categorize them based on app functions...
March 3, 2017: JMIR Human Factors
https://www.readbyqxmd.com/read/28236956/financial-incentives-for-improving-adherence-to-maintenance-treatment-in-patients-with-psychotic-disorders-money-for-medication-a-multicentre-open-label-randomised-controlled-trial
#19
Ernst L Noordraven, André I Wierdsma, Peter Blanken, Anthony F T Bloemendaal, Anton B P Staring, Cornelis L Mulder
BACKGROUND: Provision of financial incentives is a promising intervention for improving adherence in patients taking antipsychotic medication. We aimed to assess the effectiveness of this intervention for improving adherence to antipsychotic depot medication in patients with psychotic disorders, irrespective of their previous compliance. METHODS: We did this multicentre, open-label, randomised controlled trial at three mental health-care institutions in secondary psychiatric care services in the Netherlands...
March 2017: Lancet Psychiatry
https://www.readbyqxmd.com/read/28195931/should-antipsychotic-medications-for-schizophrenia-be-given-for-a-lifetime-a-naturalistic-long-term-follow-up-study
#20
Ira D Glick, John M Davis, Daisy Zamora, Jacob Ballon, Meena Nuthi
BACKGROUND: Schizophrenia remains a major health problem despite antipsychotic medications that, for most patients, can decrease acute symptoms, decrease relapses, and contribute to partial and sometimes strong positive response in patients with chronic symptoms. What has not been clear-because a double-blind, randomized, placebo-controlled trial is not feasible or ethical-is how many years after the initial episode, or onset of antipsychotic treatment, should medication be continued to achieve the best global outcome...
April 2017: Journal of Clinical Psychopharmacology
keyword
keyword
110266
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"